{
  "id": 16842978,
  "title": "GC Cell Presents GCC2005 Phase 1a Progress",
  "url": "https://urgent.news/2026/10/28/gc-cell-presents-gcc2005-phase-1a-progress",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-28T04:04:51.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=279853"
  },
  "original_language": "en",
  "account": "GC Cell presented the interim results of Phase 1a clinical trials for its allogeneic CAR-NK cell therapy GCC2005 at the 2026 Eastern Breeze Symposium on Malignant Lymphoma. The event, held in October, is an international academic conference focusing on lymphoma. The symposium marked the 20th anniversary of the Lymphoma Working Party of the Korean Society of Hematology, a professional organization dedicated to finding diagnostic and therapeutic solutions for malignant lymphoma. Ko Young-il, a professor at Seoul National University Hospital, presented the technology behind GCC2005, emphasizing the progress made in domestic lymphoma research over the past two decades. GC Cell is now conducting a domestic Phase 1b clinical trial to expedite commercialization of the therapy. The company plans to disclose the full Phase 1a data at major international conferences within the year. GC Cell's CEO, Won Seong-yong, stated that the company will continue discussions with experts at major academic conferences worldwide to promote GCC2005's clinical potential, and will maintain the ongoing Phase 1b trial without interruption.",
  "summary": "GC Cell has shared clinical progress on 'GCC2005,' an allogeneic CAR-NK cell therapy it is developing for the treatment of refractory T-cell lymphoma, on the international stage.The company said it gave an invited presentation on the interim results of the Phase 1a clinical trial of GCC2005 at the '",
  "key_points": [
    "GC Cell presented Phase 1a interim results for GCC2005 at Eastern Breeze Symposium in October 2026",
    "Symposium marked 20th anniversary of Lymphoma Working Party of Korean Society of Hematology",
    "GC Cell conducting domestic Phase 1b trial to expedite commercialization of GCC2005"
  ],
  "editors_take": "Advancing to Phase 1b trials signals GC Cell's commitment to accelerating the commercialization of its allogeneic CAR-NK cell therapy for patients battling malignant lymphoma.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}